TILT has multiple oncolytic immunotherapies for solid tumors in its pipeline.
A set of Phase I clinical trials of TILT-123 in various indications both as a monotherapy and in combination with immune checkpoint inhibitors or tumor-infiltrating lymphocyte (TIL) therapy have been completed with about 100 patients dosed across the studies. Patient enrollment for the Phase I trials listed below has now been completed.
For more information on contemplated future studies with the Phase II ready TILT-123.
TILT has a pipeline of early-stage assets & proprietary platform called TILT® technology.
Our Technology
The power of TILT® technology enables TILT’s proprietary oncolytic viruses to be encoded with immunostimulatory cytokines and molecules, which have potential applicability across a wide range of solid tumor cancers.
Learn more about how the technology works: